Hypocretin/Orexin neurons (also known as hypocretin cells or orexin-producing neurons) are a specialized population of neurons located primarily in the lateral hypothalamus that play a critical role in regulating wakefulness, arousal, feeding behavior, and energy homeostasis. These neurons are central to the pathophysiology of narcolepsy and have emerging roles in Parkinson's disease (PD), Alzheimer's disease (AD), and other neurodegenerative disorders[1].
Hypocretin/orexin neurons, also called orexinergic neurons, are located in the lateral hypothalamus, perifornical nucleus, and dorsomedial hypothalamus. Approximately 70,000-80,000 hypocretin neurons exist in the human brain, projecting widely throughout the central nervous system to regulate arousal, reward, and metabolism. These neurons produce two neuropeptides—hypocretin-1 (orexin-A) and hypocretin-2 (orexin-B)—derived from the preprohypocretin precursor encoded by the HCRT gene[2].
Hypocretin neurons are concentrated in:
Hypocretin neurons receive input from:
Widespread projections to:
Hypocretin neuron loss is a hallmark finding in PD:
Research Evidence:
In AD, hypocretin system changes include:
| Agent | Mechanism | Status | Application |
|---|---|---|---|
| Pitolisant | Histamine H3 antagonist, increases wakefulness | Approved | Narcolepsy, EDS in PD |
| Suvorexant | Dual orexin receptor antagonist | Approved | Insomnia |
| Lemborexant | Dual orexin receptor antagonist | Approved | Insomnia |
Hypocretin/orexin neurons are essential regulators of arousal, metabolism, and reward. Their significant loss in Parkinson's disease and narcolepsy makes them important therapeutic targets. Understanding hypocretin system dysfunction in neurodegenerative diseases provides opportunities for biomarker development and treatment strategies.
Peyron C, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. 2000. ↩︎
Thannickal TC, et al. Reduced number of hypocretin neurons in human narcolepsy. 2000. ↩︎
Honda M, et al. A novel neuropeptide related to frog sleep-inducing peptide in human narcolepsy. 1999. ↩︎
Fronczek R, et al. Hypocretin (orexin) loss in Parkinson's disease. 2007. ↩︎
Roth J, et al. Hypocretin/orexin deficiency in Alzheimer's disease. 2013. ↩︎
Dauvilliers Y, et al. Pitolisant for daytime sleepiness in Parkinson's disease. 2020. ↩︎